BusinessImmune Therapeutics Signs Memorandum of Understanding for Distribution of Lodonal™ in Côte d’Ivoire and acquires COPP for Côte d’Ivoire; Company Plans for Approval of Lodonal in Côte d’Ivoire in 2017By Nasdaq OMXMay 31, 2017, 1:33 PM UTC
BusinessImmune Therapeutics, Inc. Files Lodonal New Drug Application in KenyaBy Nasdaq OMXApr 25, 2017, 3:37 PM UTC
BusinessImmune Therapeutics Clears Critical Regulatory Hurdle for Lodonal in KenyaBy Nasdaq OMXApr 17, 2017, 3:45 PM UTC
BusinessImmune Therapeutics, Inc. Strengthens Balance Sheet With Debt SettlementBy Nasdaq OMXApr 12, 2017, 5:36 PM UTC
BusinessImmune Therapeutics, Inc. Announces Expansion of Patent PortfolioBy Nasdaq OMXMar 30, 2017, 1:46 PM UTC
